Ocular Therapeutix (OCUL) Amortization of Deferred Charges (2013 - 2026)

Ocular Therapeutix's Amortization of Deferred Charges history runs 14 years deep, the most recent figure standing at $1.4 million for Q1 2026.

• In Q1 2026, Amortization of Deferred Charges fell 3.83% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $3.3 million (up 4.37% YoY), while the FY2025 annual figure was $3.4 million, down 9.03% from the prior year.
• Amortization of Deferred Charges was $1.4 million for Q1 2026 at Ocular Therapeutix, up from $495000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $2.1 million in Q3 2023 to a low of $495000.0 in Q4 2025.
• Historically, Amortization of Deferred Charges has averaged $1.1 million across 5 years, with a median of $1.2 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Amortization of Deferred Charges soared 69.14% in 2023, then tumbled 70.03% in 2024.
• A 5-year view of Amortization of Deferred Charges shows it stood at $1.2 million in 2022, then advanced by 25.55% to $1.6 million in 2023, then slumped by 62.91% to $576000.0 in 2024, then slipped by 14.06% to $495000.0 in 2025, then jumped by 178.99% to $1.4 million in 2026.
• The last three Amortization of Deferred Charges figures came in at $1.4 million (Q1 2026), $495000.0 (Q4 2025), and $758000.0 (Q3 2025), per Business Quant data.